European Union - English - EMA (European Medicines Agency)

h. lundbeck a/s - nalmefene hydrochloride dihydrate - alcohol-related disorders - drugs used in alcohol dependence - selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level (see section 5.1), without physical withdrawal symptoms and who do not require immediate detoxification.selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.selincro should be initiated only in patients who continue to have a high drinking-risk level two weeks after initial assessment.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - mycophenolate mofetil 250mg;   - capsule - 250 mg - active: mycophenolate mofetil 250mg   excipient: croscarmellose sodium gelatin   hyprolose indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc sodium laurilsulfate   tekprint black sw-9008 titanium dioxide   water   - myaccord is indicated for the prophylaxis of acute organ rejection in patients receiving allogeneic renal transplants.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - mycophenolate mofetil 500mg;   - film coated tablet - 500 mg - active: mycophenolate mofetil 500mg   excipient: croscarmellose sodium hyprolose magnesium stearate microcrystalline cellulose opadry purple 03b50110 povidone purified talc - for the prophylaxis of acute organ rejection in patients receiving allogeneic renal transplants.

Ireland - English - HPRA (Health Products Regulatory Authority)

pliva pharma limited - polymyxin b sulfate ; bacitracin zinc - unknown - international unit - bacitracin

Ireland - English - HPRA (Health Products Regulatory Authority)

smith & nephew pharmaceuticals - zinc oxide - impregnated dressing - %v/v - zinc bandages

Malta - English - Medicines Authority

bayer public limited company 400 south oak way, reading berkshire rg2 6ad, united kingdom - zinc oxide, lidocaine hydrochloride - ointment - zinc oxide 6.6 % (w/w) lidocaine hydrochloride 0.7 % (w/w) - vasoprotectives

Malta - English - Medicines Authority

bayer public limited company 400 south oak way, reading berkshire rg2 6ad, united kingdom - zinc oxide, lidocaine hydrochloride - suppository - zinc oxide 283.5 mg lidocaine hydrochloride 13.2 mg - vasoprotectives

Philippines - English - FDA (Food And Drug Administration)

united douglas pharma phils inc - aluminum hydroxide , magnessium carbinate - tablet - 250mg/160mg

European Union - English - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva pharma b.v. is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva pharma b.v. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. 

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh  - clopidogrel - peripheral vascular diseases - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome:- non st segment elevation acute coronary syndrome (unstable angina or non q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.